CL2024000077A1 - Composiciones farmacéuticas de un anticuerpo contra pd-1 y uso de las mismas - Google Patents
Composiciones farmacéuticas de un anticuerpo contra pd-1 y uso de las mismasInfo
- Publication number
- CL2024000077A1 CL2024000077A1 CL2024000077A CL2024000077A CL2024000077A1 CL 2024000077 A1 CL2024000077 A1 CL 2024000077A1 CL 2024000077 A CL2024000077 A CL 2024000077A CL 2024000077 A CL2024000077 A CL 2024000077A CL 2024000077 A1 CL2024000077 A1 CL 2024000077A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical compositions
- antibody against
- retifanlimab
- treatment
- containers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220006P | 2021-07-09 | 2021-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000077A1 true CL2024000077A1 (es) | 2024-08-23 |
Family
ID=82608118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000077A CL2024000077A1 (es) | 2021-07-09 | 2024-01-09 | Composiciones farmacéuticas de un anticuerpo contra pd-1 y uso de las mismas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12364756B2 (https=) |
| EP (1) | EP4366692A1 (https=) |
| JP (1) | JP2024525566A (https=) |
| KR (1) | KR20240035533A (https=) |
| CN (1) | CN118215465A (https=) |
| AR (1) | AR126404A1 (https=) |
| AU (1) | AU2022307332A1 (https=) |
| CA (1) | CA3224640A1 (https=) |
| CL (1) | CL2024000077A1 (https=) |
| CO (1) | CO2024000198A2 (https=) |
| CR (1) | CR20240065A (https=) |
| EC (1) | ECSP24008791A (https=) |
| IL (1) | IL309985A (https=) |
| MX (1) | MX2024000268A (https=) |
| PE (1) | PE20240797A1 (https=) |
| TW (1) | TW202308694A (https=) |
| WO (1) | WO2023283049A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1946776T (pt) * | 2002-02-27 | 2017-03-17 | Immunex Corp | Composição de tnfr-fc estabilizada compreendendo arginina |
| WO2017019846A1 (en) * | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US12150990B2 (en) * | 2017-11-02 | 2024-11-26 | Nanjing Shunxin Pharmaceutical Co., Ltd. | Pharmaceutical composition of humanized monoclonal anti-PD-L1 antibody |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| CN110404066B (zh) * | 2018-04-28 | 2022-06-17 | 齐鲁制药有限公司 | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 |
| EP4007602A1 (en) * | 2019-08-01 | 2022-06-08 | Incyte Corporation | A dosing regimen for an ido inhibitor |
| PH12022550244A1 (en) * | 2019-08-05 | 2022-12-12 | Nat Cancer Ct | Biomarkers for determining the efficacy of immune checkpoint inhibitors |
-
2022
- 2022-06-22 US US17/847,094 patent/US12364756B2/en active Active
- 2022-06-22 EP EP22744039.3A patent/EP4366692A1/en active Pending
- 2022-06-22 CA CA3224640A patent/CA3224640A1/en active Pending
- 2022-06-22 AU AU2022307332A patent/AU2022307332A1/en active Pending
- 2022-06-22 IL IL309985A patent/IL309985A/en unknown
- 2022-06-22 MX MX2024000268A patent/MX2024000268A/es unknown
- 2022-06-22 KR KR1020247004643A patent/KR20240035533A/ko active Pending
- 2022-06-22 JP JP2024500249A patent/JP2024525566A/ja active Pending
- 2022-06-22 CR CR20240065A patent/CR20240065A/es unknown
- 2022-06-22 PE PE2024000052A patent/PE20240797A1/es unknown
- 2022-06-22 WO PCT/US2022/034493 patent/WO2023283049A1/en not_active Ceased
- 2022-06-22 CN CN202280059325.XA patent/CN118215465A/zh active Pending
- 2022-07-05 TW TW111125067A patent/TW202308694A/zh unknown
- 2022-07-07 AR ARP220101785A patent/AR126404A1/es unknown
-
2024
- 2024-01-09 CL CL2024000077A patent/CL2024000077A1/es unknown
- 2024-01-11 CO CONC2024/0000198A patent/CO2024000198A2/es unknown
- 2024-02-02 EC ECSENADI20248791A patent/ECSP24008791A/es unknown
-
2025
- 2025-07-21 US US19/275,898 patent/US20250345422A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023283049A1 (en) | 2023-01-12 |
| TW202308694A (zh) | 2023-03-01 |
| CA3224640A1 (en) | 2023-01-12 |
| MX2024000268A (es) | 2024-01-31 |
| KR20240035533A (ko) | 2024-03-15 |
| CN118215465A (zh) | 2024-06-18 |
| AU2022307332A1 (en) | 2024-01-18 |
| ECSP24008791A (es) | 2024-03-01 |
| JP2024525566A (ja) | 2024-07-12 |
| US20230025464A1 (en) | 2023-01-26 |
| EP4366692A1 (en) | 2024-05-15 |
| CO2024000198A2 (es) | 2024-02-05 |
| IL309985A (en) | 2024-03-01 |
| US12364756B2 (en) | 2025-07-22 |
| AR126404A1 (es) | 2023-10-11 |
| CR20240065A (es) | 2024-04-08 |
| PE20240797A1 (es) | 2024-04-18 |
| US20250345422A1 (en) | 2025-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Falto-Aizpurua et al. | Emerging treatments in alopecia | |
| JOP20220163B1 (ar) | مركب بيريدازينيل-ثيازول كربوكساميد | |
| CL2023002505A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas | |
| BR112023015715A2 (pt) | Inibidor de cdk | |
| CR20190497A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| MX2021000299A (es) | Preparados combinados para el tratamiento contra el cancer o infecciones. | |
| CL2023003965A1 (es) | Inhibidores cdk2. | |
| MX2019002564A (es) | Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas. | |
| BRPI0407375A (pt) | Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos | |
| CL2019002671A1 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. | |
| BR112022008558A2 (pt) | Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso | |
| BR112020009655A8 (pt) | Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica | |
| CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
| MX2023001963A (es) | Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. | |
| CL2025003071A1 (es) | Formas cristalinas de inhibidores de ras, composiciones que las contienen y su uso. | |
| PH12020551057A1 (en) | Group b adenovirus-containing formulation | |
| CL2025002366A1 (es) | Compuesto que contiene trifluorometilsulfonilo. | |
| DOP2025000104A (es) | Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas | |
| Wang et al. | Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination | |
| MX2021008022A (es) | Proteínas heterodiméricas para modular células t gamma delta. | |
| BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
| ECSP22049665A (es) | M?TODO PARA EL TRATAMIENTO DE C?NCER UTILIZANDO C?LULA ADYUVANTE ARTIFICIAL (aAVC) | |
| MX2021013888A (es) | Composiciones que comprenden efedrina o una sal de efedrina y metodos de fabricacion y uso de las mismas. | |
| MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. | |
| CL2024000077A1 (es) | Composiciones farmacéuticas de un anticuerpo contra pd-1 y uso de las mismas |